ALK and cancer: In addition, significant differences in gene expression were observed by RNA-seq analysis when comparing transcriptional profiles of acutely treated cells (48 hours), DTPs, and cells exhibiting acquired resistance across EGFR-mutant and ALK fusion-positive cancer cell lines under therapy (Supplementary Fig. 2d–f, Supplementary Data 2).